166 related articles for article (PubMed ID: 17159126)
21. [Bing-Neel syndrome. Polyneuropathy within the scope of paraproteinemia].
Seitzer B; Spieker C; Schoon ML; Zidek W
Fortschr Med; 1989 Apr; 107(13):291-3. PubMed ID: 2722107
[TBL] [Abstract][Full Text] [Related]
22. [Polyneuropathy and monoclonal IgG/IgA gammopathy--differential neurography on the basis of two patient cases].
Abler B; Gdynia HJ; von Arnim CA
Fortschr Neurol Psychiatr; 2009 Feb; 77(2):105-9. PubMed ID: 19221974
[TBL] [Abstract][Full Text] [Related]
23. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
24. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies.
Lopate G; Choksi R; Pestronk A
Muscle Nerve; 2002 Jun; 25(6):828-36. PubMed ID: 12115971
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal gammopathies and malignancies in patients with chronic urticaria.
Karakelides M; Monson KL; Volcheck GW; Weiler CR
Int J Dermatol; 2006 Sep; 45(9):1032-8. PubMed ID: 16961504
[TBL] [Abstract][Full Text] [Related]
26. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
27. Subacute demyelinating polyneuropathy in B-cell lymphoma with IgM antibodies against glycolipid GD1b.
Marfia GA; Pachatz C; Terracciano C; Leone G; Bernardini S; Bernardi G; Massa R
Neurol Sci; 2005 Dec; 26(5):355-7. PubMed ID: 16388373
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulins in chronic inflammatory demyelinating polyneuropathy.
Comi G; Quattrini A; Fazio R; Roveri L
Neurol Sci; 2003 Oct; 24 Suppl 4():S246-50. PubMed ID: 14598053
[TBL] [Abstract][Full Text] [Related]
29. IgA monoclonal gammopathy of undetermined significance with peripheral neuropathy.
Mehndiratta MM; Sen K; Tatke M; Bajaj BK
J Neurol Sci; 2004 Jun; 221(1-2):99-104. PubMed ID: 15178222
[TBL] [Abstract][Full Text] [Related]
30. Characterization of neuropathies associated with elevated IgM serum levels.
Goldfarb AR; Sander HW; Brannagan TH; Magda P; Latov N
J Neurol Sci; 2005 Feb; 228(2):155-60. PubMed ID: 15694197
[TBL] [Abstract][Full Text] [Related]
31. IgM MGUS associated with anti-MAG neuropathy: a single institution experience.
Talamo G; Mir MA; Pandey MK; Sivik JK; Raheja D
Ann Hematol; 2015 Jun; 94(6):1011-6. PubMed ID: 25572169
[TBL] [Abstract][Full Text] [Related]
32. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.
Wilson HC; Lunn MP; Schey S; Hughes RA
J Neurol Neurosurg Psychiatry; 1999 May; 66(5):575-80. PubMed ID: 10209166
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of a population based cohort with monoclonal proteinaemia.
Schaar CG; le Cessie S; Snijder S; Franck PF; Wijermans PW; Ong C; Kluin-Nelemans H
Br J Haematol; 2009 Jan; 144(2):176-84. PubMed ID: 19036113
[TBL] [Abstract][Full Text] [Related]
35. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
36. Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy.
Eurelings M; Lokhorst HM; Notermans NC; Krijtenburg PJ; Kessel Bv; Eleveld MJ; Bloem A; Wokke JH; Poot M; Buijs A
J Neurol Sci; 2007 Sep; 260(1-2):124-31. PubMed ID: 17543994
[TBL] [Abstract][Full Text] [Related]
37. Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance.
Dizdar O; Erman M; Cankurtaran M; Halil M; Ulger Z; Yavuz BB; Ariogul S; Pinar A; Harputluoglu H; Kars A; Celik I
Ann Hematol; 2008 Jan; 87(1):57-60. PubMed ID: 17874101
[TBL] [Abstract][Full Text] [Related]
38. Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance.
Kelly JJ
Rev Neurol Dis; 2008; 5(1):14-22. PubMed ID: 18418318
[TBL] [Abstract][Full Text] [Related]
39. Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy.
Lehmann HC; Hoffmann FR; Meyer Zu Hörste G; Hartung HP; Kieseier BC
Eur J Neurol; 2010 Aug; 17(8):1075-81. PubMed ID: 20236302
[TBL] [Abstract][Full Text] [Related]
40. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
